Monday, December 05, 2016
 
 
Video: Page (1) of 1 - 01/29/13 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
Stemline Therapeutics Announces Pricing of IPO

By DMO Affiliate
Stemline Therapeutics, a clinical-stage biopharmaceutical company developing oncology therapeutics that target both cancer stem cells and tumor bulk, today announced the pricing of its IPO of 3,317,644 shares of its common stock offered at a price to the public of $10.00 per share. The gross proceeds to Stemline from the initial public offering are expected to be $33,176,440, before underwriting discounts and commissions and other offering expenses.
Stemline Therapeutics Announces Pricing of IPO




Page: 1


null
 
 
 
 
 
 
 
 
 
 
 





Our Privacy Policy --- About The U.S. Daily News - Contact Us - Advertise With Us - Privacy Guidelines